|I am time constrained, appreciate your thoughtful responses. Thought I might have imagined or mistakenly attributed another biotech on the point of European trials. But I did get that right: July 29 news. |
Shawn Shirazi, PhD, chief executive officer -- drug division, Theralase, stated that: "The enrolment of the first patient at UHN represents a major milestone for Theralase. I am pleased that the phase II ACT-NMIBC clinical study has enrolled and will be treating its first patient. Our primary focus has been to on board sites in Canada followed by the U.S. and Europe; however, as we have been successful in signing an agreement with a trial management organization (TMO) in the U.S., we no longer will be proceeding with European study site on boarding at this time. The addition of the TMO has increased the anticipated number of U.S. clinical sites, thereby negating the need to open up European sites and ultimately a significant cost savings for the company."